Trademark: 88173138
Word
SECOND BRAIN
Status
Dead
Status Code
604
Status Date
Monday, March 9, 2020
Serial Number
88173138
Mark Type
4000
Filing Date
Monday, October 29, 2018
Published for Opposition
Tuesday, October 8, 2019
Abandoned Date
Monday, March 9, 2020

Trademark Owner History
BIOHM HEALTH LLC - Owner At Publication
PathoBiome LLC - Original Applicant

Classifications
5 Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and/or minerals and/or essential fatty acids and/or probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and/or minerals and/or essential fatty acids and/or probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; preparations in the nature of a vaginal probiotic for the treatment and/or prevention of bacterial or fungal vaginal infection; nutraceuticals for the treatment and/or prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibers in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibers in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, including, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; microbial and biological preparations for improving the physical well-being of humans, namely, reducing inflammation and pain; supplements, namely, dietary supplements, for medical use and baby food, all the above containing preparations and products resulting from the processing of microorganisms, particularly metabolites obtained from the processing of probiotic bacterial cultures; probiotic and/or nutritional and dietary supplements vaginal antifungal preparations; fungal and/or bacterial probiotics, and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's Disease, ulcerative colitis and irritable bowel syndrome; nutritional supplements, namely, probiotic compositions; diagnostic test kit comprised of medical diagnostic reagents and assays for the detection of bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the gastrointestinal tract; diagnostic test kit comprised of medical diagnostic reagents and assays for the detection of bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the large intestine; diagnostic colon test kit comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, Crohn's disease, ulcerative colitis, and irritable bowel syndrome; diagnostic colon cancer test kit comprised of medical diagnostic reagents and assays; diagnostic colorectal cancer screening test kit comprised of medical diagnostic reagents and assays; all of the aforementioned supplements and pharmaceutical products for human consumption containing probiotics; all of the aforementioned diagnostic kits testing levels of probiotics
44 Medical diagnostic testing services to detect bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the gastrointestinal tract; Medical diagnostic testing services to detect bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the large intestine; Medical diagnostic testing services to apprise individuals and/or animals of the status of the gastrointestinal tract; Medical diagnostic testing services to apprise individuals and/or animals of the status of the large intestine; providing medical information comprised of a personalized report comparing detected levels of bacteria, fungus, microorganisms, probiotics, cancer and/or pathogen in the gastrointestinal tract; providing medical information comprised of a personalized report comparing detected levels of bacteria, fungus, microorganisms, probiotics, cancer and/or pathogen in the large intestine; providing educational information in the field of the gastrointestinal tract and the existence and reason for bacteria, fungus, microorganism, probiotics, cancer and/or pathogens in the gastrointestinal tract; providing educational information in the field of the gastrointestinal tract and the existence and reason for bacteria, fungus, microorganism, probiotics, cancer and/or pathogens in the large intestine; providing educational information in the field of the gastrointestinal tract and how to have and maintain and/or monitor a healthy gastrointestinal tract; providing educational information in the field of the gastrointestinal tract and how to have and maintain and/or monitor a healthy large intestine

Trademark Events
Mar 9, 2020
Abandonment Notice E-Mailed - Inter Partes Decision
Mar 9, 2020
Abandonment - After Inter Partes Decision
Mar 9, 2020
Opposition Terminated No. 999999
Mar 9, 2020
Opposition Sustained No. 999999
Dec 6, 2019
Opposition Instituted No. 999999
Nov 5, 2019
Extension Of Time To Oppose Received
Oct 8, 2019
Official Gazette Publication Confirmation E-Mailed
Oct 8, 2019
Published For Opposition
Sep 18, 2019
Notification Of Notice Of Publication E-Mailed
Sep 5, 2019
Assigned To Lie
Aug 30, 2019
Approved For Pub - Principal Register
Aug 13, 2019
Teas/Email Correspondence Entered
Aug 13, 2019
Correspondence Received In Law Office
Aug 13, 2019
Teas Response To Office Action Received
Feb 28, 2019
Notification Of Non-Final Action E-Mailed
Feb 28, 2019
Non-Final Action E-Mailed
Feb 28, 2019
Non-Final Action Written
Feb 4, 2019
Assigned To Examiner
Jan 30, 2019
Automatic Update Of Assignment Of Ownership
Nov 13, 2018
New Application Office Supplied Data Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24